Drug Profile
Rilotumumab companion diagnostic - Dako
Latest Information Update: 27 Nov 2014
Price :
$50
*
At a glance
- Originator Dako A/S
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 24 Nov 2014 No development reported - Clinical-Phase-Unknown for Cancer (Diagnosis) in Europe (unspecified route)
- 24 Nov 2014 No development reported - Clinical-Phase-Unknown for Cancer (Diagnosis) in USA (unspecified route)
- 21 Jun 2012 Dako A/S has been acquired by Agilent Technologies